Remove Clinical Research Remove Clinical Trials Remove Compliance Remove Cosmetics
article thumbnail

Leveraging AI-Enabled Data Extraction to Accelerate Case Processing in Clinical Trials

Cloudbyz

AI-enabled data extraction holds immense promise in expediting case processing within clinical trials, offering a transformative approach to streamline workflows and enhance efficiency. In this blog, we delve into the potential of AI in pharmacovigilance and its implications for clinical trial safety monitoring.

article thumbnail

Clinical Research Data Transparency with Darshan Kulkarni

Clinical Trial Podcast

Who owns the clinical trial data generated in industry sponsored or investigator initiated clinical trials? What responsibilities do Sponsors, CROs, or Sites have when it comes to sharing clinical trial results with patients? To answer these questions and more, I invited Darshan Kulkarni to the show.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Accelerating Consumer Product Research with Unified Clinical Trial Management Solutions

Cloudbyz

The pursuit for the most effective and safe products requires rigorous clinical research, which involves meticulous trial design, recruitment, data collection, and subsequent analysis. A delay in trials or approval can significantly impact the product’s success and the company’s bottom line.

article thumbnail

Why a Platform Approach is Vital for Clinical Research Management Transformation

Cloudbyz

The clinical research landscape is rapidly evolving. As it becomes more complex with growing volumes of data, evolving regulations, and the pressure for faster drug development, traditional methods of clinical research management are no longer sufficient. This is where the platform approach comes into play.

article thumbnail

FDA End-of-Year Release of Warning Letters Impresses (or Depresses)

FDA Law Blog

Warning Letters, generally made public in a batch each Tuesday, are FDA’s public sanction that is most widely used to bring pressure on manufacturers and clinical trial investigators. Patcos Cosmetics Pvt. Finally, FDA said in a Warning Letter that a Clinical Investigator, Anish S. Shah, M.D.,